Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study.
Lanzillo R, Carotenuto A, Signoriello E, Iodice R, Miele G, Bisecco A, Maniscalco GT, Sinisi L, Romano F, Di Gregorio M, Lavorgna L, Trojsi F, Moccia M, Fratta M, Capasso N, Dubbioso R, Petracca M, Spiezia AL, Gallo A, Petruzzo M, De Angelis M, Bonavita S, Lus G, Tedeschi G, Brescia Morra V. Lanzillo R, et al. Among authors: di gregorio m. J Clin Med. 2022 Apr 7;11(8):2081. doi: 10.3390/jcm11082081. J Clin Med. 2022. PMID: 35456175 Free PMC article.
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group. Prosperini L, et al. J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26. J Neurol. 2018. PMID: 30259178
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study.
Di Gregorio M, Torri Clerici VLA, Fenu G, Gaetani L, Gallo A, Cavalla P, Ragonese P, Annovazzi P, Gajofatto A, Prosperini L, Landi D, Nicoletti CG, Di Carmine C, Totaro R, Nociti V, De Fino C, Ferraro D, Tomassini V, Tortorella C, Righini I, Amato MP, Manni A, Paolicelli D, Iaffaldano P, Lanzillo R, Moccia M, Buttari F, Fantozzi R, Cerqua R, Zagaglia S, Farina D, De Luca G, Buscarinu MC, Pinardi F, Cocco E, Gasperini C, Solaro CM, Di Filippo M. Di Gregorio M, et al. Among authors: di carmine c, di filippo m. Eur J Neurol. 2021 Apr;28(4):1299-1307. doi: 10.1111/ene.14672. Epub 2021 Jan 12. Eur J Neurol. 2021. PMID: 33305459
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study.
Petracca M, Ruggieri S, Barbuti E, Ianniello A, Fantozzi R, Maniscalco GT, Andreone V, Landi D, Marfia GA, Di Gregorio M, Iodice R, Sinisi L, Maida E, Missione R, Coppola C, Bonavita S, Borriello G, Centonze D, Lus G, Pozzilli C, Signoriello E. Petracca M, et al. Among authors: di gregorio m. Neurol Ther. 2022 Sep;11(3):1193-1208. doi: 10.1007/s40120-022-00364-6. Epub 2022 Jun 2. Neurol Ther. 2022. PMID: 35653061 Free PMC article.
Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs.
Capuano R, Prosperini L, Altieri M, Lorefice L, Fantozzi R, Cavalla P, Guaschino C, Radaelli M, Cordioli C, Nociti V, Boffa L, Ragonese P, Di Gregorio M, Pinardi F, Torri Clerici V, De Luca G, Gajofatto A, Paolicelli D, Tortorella C, Gasperini C, Solaro C, Cocco E, Bisecco A, Gallo A. Capuano R, et al. Among authors: di gregorio m. Mult Scler. 2023 Jun;29(7):856-865. doi: 10.1177/13524585231167515. Epub 2023 May 11. Mult Scler. 2023. PMID: 37165941 Free PMC article.
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab.
Signoriello E, Signori A, Lus G, Romano G, Marfia GA, Landi D, Napoli F, D' Amico E, Zanghí A, Di Filippo PS, Caliendo D, Carotenuto A, Spiezia AL, Fantozzi R, Centonze D, Lucchini M, Mirabella M, Cocco E, Frau J, Maniscalco GT, Di Battista ME, Foschi M, Surcinelli A, Bonavita S, Abbadessa G, Pasquali L, Di Gregorio M, Ferrò MT, Sormani MP, Schiavetti I; ON focus study group. Signoriello E, et al. Among authors: di gregorio m. Mult Scler Relat Disord. 2024 Jul;87:105594. doi: 10.1016/j.msard.2024.105594. Epub 2024 Apr 6. Mult Scler Relat Disord. 2024. PMID: 38718748 Free article.
The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT).
Bianchi A, Matranga D, Patti F, Maniscalco L, Pilotto S, Di Filippo M, Zaffaroni M, Annovazzi P, Bertolotto A, Gasperini C, Quartuccio E, Centonze D, Fantozzi R, Gajofatto A, Gobbin F, Landi D, Granella F, Buccafusca M, Marfia GA, Chisari C, Naldi P, Bergamaschi R, Greco G, Zarbo IR, Rizzo V, Ulivelli M, Bezzini D, Florio L, Turazzini M, Di Gregorio M, Pugliatti M, Salemi G, Ragonese P; the MS-MigIT Study Group. Bianchi A, et al. Among authors: di gregorio m. J Neurol. 2024 May;271(5):2182-2194. doi: 10.1007/s00415-024-12214-6. Epub 2024 Feb 16. J Neurol. 2024. PMID: 38366072 Free PMC article.
Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica.
Di Filippo M, Franciotta D, Massa R, Di Gregorio M, Zardini E, Gastaldi M, Terracciano C, Rastelli E, Gaetani L, Iannone A, Menduno P, Floridi P, Sarchielli P, Calabresi P. Di Filippo M, et al. Among authors: di gregorio m. Neurology. 2012 Sep 11;79(11):1182-4. doi: 10.1212/WNL.0b013e3182698d39. Epub 2012 Aug 29. Neurology. 2012. PMID: 22933739 Free PMC article. No abstract available.
134 results